VITROS Immunodiagnostic Products NT-proBNP II

CompletedOBSERVATIONAL
Enrollment

3,246

Participants

Timeline

Start Date

June 6, 2018

Primary Completion Date

October 17, 2019

Study Completion Date

October 17, 2019

Conditions
Heart Failure
Interventions
DIAGNOSTIC_TEST

VITROS Immunodiagnostic Products

NT-proBNP II assay

Trial Locations (25)

10461

Montefiore Medical Center, The Bronx

19107

Thomas Jefferson University, Philadelphia

21201

University of Maryland (Baltimore & St. Joseph), Baltimore

22042

INOVA Healthcare Services, Falls Church

27157

Wake Forest University Health Sciences, Winston-Salem

28203

Charlotte-Mecklenburg Hospital Authority (Carolinas Healthcare System), Charlotte

36106

Drug Research Analysis Corp, Montgomery

37232

Vanderbilt University Medical Center, Nashville

44195

Cleveland Clinic Foundation, Cleveland

45229

University of Cincinnati Physicians Company, Cincinnati

46202

Indiana University Health Hospital (Eskenazi & Methodist), Indianapolis

48073

William Beaumont Hospital (Royal Oak & Troy), Royal Oak

48201

Wayne State University (Harper), Detroit

48202

Henry Ford Health System, Detroit

60208

Northwestern University, Evanston

70791

Southern Clinical Research, Zachary

75390

University of Texas Southwestern Medical Center, Dallas

77030

Baylor College of Medicine (Ben Taub), Houston

78215

Sun Research Institute, San Antonio

85724

University of Arizona Banner - University Medical Center South Campus, Tucson

89121

Clinical Research of South Nevada, Las Vegas

90211

Westside Medical Associates of Los Angeles, Beverly Hills

92093

University of California San Diego Health, San Diego

95817

University of California Davis Health, Sacramento

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Ortho-Clinical Diagnostics, Inc.

INDUSTRY

NCT03548909 - VITROS Immunodiagnostic Products NT-proBNP II | Biotech Hunter | Biotech Hunter